A naukri.com initiative
Bloomberg Quint
12h
227
Image Credit: Bloomberg Quint
Natco Pharma Q2 Results Review - Strong Quarter, Pipeline Build-Up Underway: ICICI Securities
- ICICI Securities has reviewed Natco Pharma's Q2 results.
- They maintain a Hold rating on the stock with a target price of Rs 1,430.
- The brokerage highlights the strong quarter and pipeline build-up underway.
- They also mention limited competition opportunities in the U.S. market.
Read Full Article
13 Likes
For uninterrupted reading, download the app